RecruitingPhase 2NCT06993974

Nitazoxanide in Patients With Ulcerative Colitis

Clinical Study to Evaluate Safety and Efficacy of Nitazoxanide in Patients With Ulcerative Colitis.

Sponsor

Alexandria University

Enrollment

70 participants

Start Date

May 30, 2025

Study Type

INTERVENTIONAL

Conditions

Ulcerative Colitis

Summary

Ulcerative colitis (UC) is a chronic inflammatory bowel Disease (IBD) that primarily affects the rectum and colon. The severity and persistence of mucosal inflammation are associated with morbidity and mortality.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether nitazoxanide — an antiparasitic drug with anti-inflammatory properties — can improve symptoms in people with mild to moderate ulcerative colitis, a chronic inflammatory bowel condition. **You may be eligible if...** - You are 18 or older - You have been diagnosed with mild to moderate ulcerative colitis, confirmed by colonoscopy and biopsy - Both men and women are eligible **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have colorectal cancer - Your ulcerative colitis is severe - You are taking rectal or systemic steroids - You are taking immunosuppressive drugs or biologics - You have an addiction to alcohol or drugs - You have a known allergy to the study medications Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGMesalamine

Mesalamine or 5-amino salicylic acid (5-ASA), plays a crucial role in the treatment of ulcerative colitis (UC). It is the first-line therapy for mild to moderate cases of UC and is considered a cornerstone in its management.

DRUGNitazoxanide

Nitazoxanide is an FDA-approved oral medication used to treat protozoal infections and is also effective against metronidazole-resistant Clostridium difficile colitis.

Locations(1)

Alexandria University

Alexandria, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06993974

Related Trials

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT0697933682 locations

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

NCT0696411319 locations

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

NCT0718500920 locations

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

NCT0544256798 locations

Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population

NCT071772091 location